External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO Virtual Plenaries 2021

-
Coming soon
06:30 PM
Duration 15mins Virtual
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (NSQ-NSCLC) with PD-L1 high expression using real-world data
Peters S, Dafni U, Perol M, Felip E, Polito L, Pal N, Ton T, Merritt D, Morris S, Stahel R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:25 PM
Duration 15mins Virtual
IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab▼ (atezo)
Stephen V. Liu, Tony S.K. Mok, Aaron S. Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Maciej Krzakowski, Alexey Smolin, Maximilian Hochmair, Marina Garassino, Carl M. Gay, John V. Heymach, Lauren A. Byers, Mark McCleland, Barzin Y. Nabet, Stefanie Morris, Leah Adler, David Shames, Martin Reck

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 PM
Duration 15mins Virtual
IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer
Huober J, Barrios CH, Niikura N, Jarzab M, Chang Y-C, Huggins-Puhalla SL, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar